BTK and Recurrent upper respiratory tract infections: Of the adverse events of clinical interest for BTK inhibitors, infections were prevalent, with 50% of patients in the ZR-CHOP group experiencing various types of infections, including pneumonia (30%), upper respiratory tract infection (15%), and urinary tract infection (15%).